Cantor Fitzgerald came away from last week’s conference with reinforced conviction on Gossamer Bio (GOSS), telling investors in a research note that sentiment is clearly improving ahead of the February 2026 PROSERA readout. The firm, which has an Overweight rating on Gossamer Bio shares, says the market is still mis-pricing seralutinib’s odds, even with the recent stock run-up.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio upgraded to Buy from Neutral at UBS
- Gossamer Bio’s Seralutinib: Promising Long-Term Therapy with Upcoming Catalysts
- Gossamer Bio Reports Q2 2025 Financial Results
- Gossamer Bio’s Promising Clinical Advancements and Strategic Positioning Earns Buy Rating
- Gossamer Bio reports Q2 EPS (17c) , consensus (18c)